Immunotherapy: Personalized Treatment for Advanced Prostate Cancer
Sandra Kelly, RN, MS, NP, Nurse Practitioner, Brigham & Women’s Hospital
Allison Tyler, RN, BSN, OCN®, CCRP, Staff Nurse, Cleveland Clinic
Published Online: Wednesday, September 19, 2012
This article describe in detail process of prescribing PROVENGE from beginning to end.
"... when a castration-resistant patient develops metastatic disease, Provenge may be considered. The 2012 National Comprehensive Cancer Network guidelines for prostate cancer indicate that for an asymptomatic or minimally symptomatic patient with metastatic disease and castration-resistant disease, Provenge may be an appropriate first-line option...
CONCLUSION
Provenge is the first and only immunotherapy approved by the US Food and Drug Administration for men with asymptomatic or minimally symptomatic metastatic castration- resistant prostate cancer. The use of this immunotherapy in the treatment of metastatic CRPC broadens treatment options by providing a clinical benefit with a safety profile you and your patients can manage. The role of nurses is critical, and they must be proactive with appropriate patient identification, education, and symptom management to achieve the maximum benefit for patients.
Historically, the only therapy available for patients with metastatic CRPC proven to provide a survival benefit has been chemotherapy. Over the past several years, new agents have been developed and approved for use in patients with advanced prostate cancer. After treatment with Provenge, those new agents may still be used as indicated, offering a multitude of treatment options for patients, where there once were few."
www.onclive.com/web-exclusives/Immunotherapy-Personalized-Treatment-for-Advanced-Prostate-CancerMeanwhile, the most popular article right now on ONCLIVE
Post Edited (HOPENEVERDIE) : 9/25/2012 9:49:36 AM (GMT-6)